Filtern
Volltext vorhanden
- ja (65)
Gehört zur Bibliographie
- ja (65)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (65) (entfernen)
Schlagworte
- ischemic stroke (6)
- mechanical thrombectomy (4)
- chemotherapy (3)
- cochlear implantation (3)
- neutrophils (3)
- thrombo-inflammation (3)
- 3D fluoroscopy (2)
- Childhood medulloblastoma (2)
- Clinical Neuroradiology (2)
- Radiotherapy (2)
- acute ischemic stroke (2)
- aortic arch (2)
- atherosclerosis (2)
- cerebellar tDCS (2)
- children (2)
- cognitive impairment (2)
- editorial (2)
- fpVCT (2)
- immunohistochemistry (2)
- intraoperative imaging (2)
- ischemic penumbra (2)
- magnetic resonance imaging (2)
- middle cerebral artery occlusion (2)
- mouse (2)
- multiple sclerosis (2)
- neurology (2)
- radiotherapy (2)
- split-belt treadmill (2)
- stroke (2)
- surgery (2)
- temporal bone (2)
- three-dimensional imaging (2)
- 3 D rotational fluoroscopy (1)
- 3D analysis (1)
- 4D flow (1)
- 4D flow MRI (1)
- APERIO (1)
- APERIO Hybrid (1)
- AQP4 (1)
- AT/RT (1)
- Activation (1)
- Adolescents (1)
- Alemtuzumab (1)
- Alzheimer’s dementia (1)
- Atherosclerosis, intracranial arteries (1)
- B cells (1)
- B7-H1 Antigen (1)
- Brain atrophy (1)
- CD19 (1)
- CD52 (1)
- CDL (1)
- CMR (1)
- CNS (1)
- CNS imaging (1)
- COVID-19 (1)
- CT (1)
- CTLA-4 Antigen (1)
- CXCL4 (1)
- CXCL7 (1)
- Chemotherapy (1)
- Childrens-cancer (1)
- Chronic heart failure (1)
- Cisplatin (1)
- Clinical Genetics (1)
- Clinical trial (1)
- Cochlear duct length (1)
- Cochlear planning software (1)
- Cognitive decline (1)
- Covid-19 (1)
- DWI (1)
- Down-regulation (1)
- Drug Therapy, Combination (1)
- EAE (1)
- EU‐RHAB Registry (1)
- Extraocular eye muscles (1)
- Fabry disease (1)
- Fibroblasts (1)
- GFAP (1)
- Gene (1)
- Glial fibrillary acidic protein (1)
- HD (1)
- HMGB1 (1)
- High-dose chemotherapy (1)
- Induced apoptosis (1)
- Lines (1)
- MPI (1)
- MPS (1)
- MR neurography (1)
- MRI (1)
- MS (1)
- MSCT (1)
- MTX (1)
- Medulloblastoma (1)
- Melanoma-cells (1)
- Memory dysfunction (1)
- Meniere’s disease (1)
- Metastases (1)
- Mucopolysaccharidosis IIIa (1)
- NAP-2 (1)
- NETs (1)
- NMOSD (1)
- NOAC (1)
- Orai2 (1)
- PET/CT (1)
- PF4 (1)
- PWV (1)
- Paediatric (1)
- Parkinson’s disease (1)
- Phase II trials (1)
- Phase-II (1)
- Primitive neuroectodermal (1)
- Programmed Cell Death 1 Receptor (1)
- R-CHOP (1)
- Recurrent medulloblastoma (1)
- Reirradiation (1)
- Relapse (1)
- Rhabdoid 2007 (1)
- Rhabdomyosarcoma (1)
- Secondary tumours (1)
- Skin Neoplasms (1)
- Suprascapular nerve (1)
- Survival (1)
- T-cells (1)
- Therapy (1)
- Treatment (1)
- Trial (1)
- Tumors (1)
- WSS (1)
- adverse events (1)
- age (1)
- anatomy (1)
- aneurysm (1)
- aneurysm surgery (1)
- angiography (1)
- balance (1)
- biochemical assays (1)
- biomarker (1)
- biomedical engineering (1)
- blood–brain barrier (1)
- bone imaging (1)
- brain cancer (1)
- brain endothelium (1)
- carotid atherosclerosis (1)
- carotid stenosis (1)
- carotid ultrasound (1)
- case report (1)
- cerebral ischemia (1)
- cerebral vasospasm (1)
- cerebrovascular disorders (1)
- cervical dystonia (1)
- characterization and analytical techniques (1)
- chemokines (1)
- childhood cancer (1)
- cholinergic activity (1)
- chronic heart failure (1)
- classification (1)
- clinical trials (1)
- clip control (1)
- cluster analysis (1)
- collateral circulation (1)
- compression syndrome (1)
- computed tomography (1)
- consolidation (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- cortical excitability (1)
- cortical silent period (1)
- crosslinked coating (1)
- degree of stenosis (1)
- diabetic polyneuropathy (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diffuse large B-cell lymphoma (1)
- disease risk-factors (1)
- dorsal root ganglion (1)
- editorial board (1)
- edoxaban (1)
- electrical and electronic engineering (1)
- electromagnetic navigation (1)
- electromyographic (1)
- encephalopathy (1)
- endoglin (1)
- endotheliitis (1)
- ependymoma (1)
- experimental stroke (1)
- facial nerve (1)
- fibromyalgia syndrome (1)
- fiducial registration error (1)
- flexible CO2 laser (1)
- flow (1)
- flow dynamics (1)
- fluoroscopy (1)
- frameless systems (1)
- functional MRI (1)
- gait (1)
- gene variant (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- german multicenter (1)
- giant cell arteritis (1)
- glial fibrillary acidic protein (1)
- glycoprotein VI (1)
- glycoprotein receptor Ib (1)
- glycoprotein receptor Ibα (1)
- guality-of-life (1)
- heart failure (1)
- hemorrhagic transformation (1)
- hepatitis B virus (1)
- hyperperfusion (1)
- hypoxia (1)
- image quality (1)
- imaging (1)
- imaging agents (1)
- imaging changes (1)
- inebilizumab (1)
- integrin α2 (1)
- intensity of attention (1)
- interelectrode-distance (1)
- intracranial bleeding (1)
- intraoperative (1)
- intraventricular therapy (1)
- journal (1)
- jugular paraganglioma (1)
- large artery vasculitis (1)
- large vessel occlusion (1)
- laser surgery (1)
- lateral skull base (1)
- length of stenosis (1)
- leukocytes (1)
- levodopa-induced dyskinesia (1)
- locomotor adaptation (1)
- long-term survivors (1)
- longitudinally extensive transverse myelitis (1)
- lymphoma (1)
- lysosomal storage disease (1)
- magnetic properties (1)
- magnetic properties and materials (1)
- magnetic resonance neurography (1)
- mapping (1)
- mass index (1)
- medical imaging (1)
- medulloblastoma (1)
- mice (1)
- microscopy (1)
- motor-evoked potentials (MEP) (1)
- nanoparticles (1)
- neck circumference (1)
- neurofilament light chain (1)
- neurological complications (1)
- neuropathic pain (1)
- neuropathy (1)
- neurosurgery (1)
- neurovascular disorders (1)
- onset craniopharyngioma (1)
- ophthalmic artery (1)
- optic nerve (1)
- optic neuritis (1)
- orbit (1)
- otology (1)
- outcome (1)
- p.R245H (1)
- p.S298P (1)
- pediatric brain tumor (1)
- pediatric low‐grade glioma (1)
- perfusion imaging (1)
- peripheral nerve involvement (1)
- peripheral nervous system (1)
- permeability imaging (1)
- phosphorylated tau protein (1)
- plaque (1)
- plaque characteristics (1)
- platelets (1)
- post-processing (1)
- prognosis (1)
- progression (1)
- proton beam therapy (1)
- pulse wave velocity (1)
- quantification (1)
- radial (1)
- re-irradiation (1)
- recombinant tissue-type plasminogen activator (1)
- recurrence (1)
- recurrent (1)
- refractory (1)
- renal function (1)
- reperfusion injury (1)
- research activity (1)
- risk of fall (1)
- saccotomy (1)
- secondary reconstruction (1)
- secondary stroke injury (1)
- self-navigation (1)
- seronegative (1)
- shedding (1)
- shoulder neurolysis (1)
- sirolimus (1)
- software (1)
- stent-retriever device (1)
- stereotaxy (1)
- subarachnoid hemorrhage (1)
- subcutaneous adipose-tissue (1)
- suprascapular notch (1)
- surgical management of paraganglioma (1)
- tMCAO (1)
- thrombemboli (1)
- thromboemboli (1)
- to-height ratio (1)
- tomography (1)
- transcranial magnetic simulation (TMS) (1)
- transient middle cerebral artery occlusion (1)
- tympanic paraganglioma (1)
- tympanojugular paraganglioma (1)
- vasa vasorum (1)
- vertebral artery (1)
- vessel diameter (1)
- vessel patency (1)
- vestibular aqueduct (VA) (1)
- visceral adiposity (1)
- wall shear stress (1)
Institut
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (65) (entfernen)
Sonstige beteiligte Institutionen
Background
Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood.
Methods
Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI).
Results
Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1).
Conclusions
pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers.
This proof of concept describes the use of evoked electromyographic (EMG) activation of the facial nerve for intraoperative monitoring of the electrode insertion during cochlear implantation (CI). Intraoperative EMG measurements from the facial nerve were conducted in nine patients undergoing CI implantation. Electric current pulses were emitted from contacts on the CI array during and immediately after electrode insertion. For control, the results of EMG measurements were compared to postoperative flat panel volume computed tomography scans with secondary reconstruction (fpVCT\(_{SECO}\)). During insertion, the EMG response evoked by the electrical stimulation from the CI was growing with the stimulating contact approaching the facial nerve and declined with increasing distance. After full insertion, contacts on the apical half of the CI array stimulated higher EMG responses compared with those on the basal half. Comparison with postoperative imaging demonstrated that electrode contacts stimulating high EMG responses had the shortest distances to the facial nerve. It could be demonstrated that electrically evoked EMG activation of the facial nerve can be used to monitor the progress during CI electrode insertion and to control the intracochlear electrode position after full insertion.
CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement
(2022)
We tested the hypothesis that reduced skin innervation in fibromyalgia syndrome is associated with specific CNS changes. This prospective case–control study included 43 women diagnosed with fibromyalgia syndrome and 40 healthy controls. We further compared the fibromyalgia subgroups with reduced (n = 21) and normal (n = 22) skin innervation. Brains were analysed for cortical volume, for white matter integrity, and for functional connectivity. Compared to controls, cortical thickness was decreased in regions of the frontal, temporal and parietal cortex in the fibromyalgia group as a whole, and decreased in the bilateral pericalcarine cortices in the fibromyalgia subgroup with reduced skin innervation. Diffusion tensor imaging revealed a significant increase in fractional anisotropy in the corona radiata, the corpus callosum, cingulum and fornix in patients with fibromyalgia compared to healthy controls and decreased FA in parts of the internal capsule and thalamic radiation in the subgroup with reduced skin innervation. Using resting-state fMRI, the fibromyalgia group as a whole showed functional hypoconnectivity between the right midfrontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. The subgroup with reduced skin innervation showed hyperconnectivity between the inferior frontal gyrus, the angular gyrus and the posterior parietal gyrus. Our results suggest that the subgroup of fibromyalgia patients with pronounced pathology in the peripheral nervous system shows alterations in morphology, structural and functional connectivity also at the level of the encephalon. We propose considering these subgroups when conducting clinical trials.
Experimental evidence has emerged that local platelet activation contributes to inflammation and infarct formation in acute ischemic stroke (AIS) which awaits confirmation in human studies. We conducted a prospective observational study on 258 consecutive patients undergoing mechanical thrombectomy (MT) due to large-vessel-occlusion stroke of the anterior circulation (08/2018-05/2020). Intraprocedural microcatheter aspiration of 1 ml of local (occlusion condition) and systemic arterial blood samples (self-control) was performed according to a prespecified protocol. The samples were analyzed for differential leukocyte counts, platelet counts, and plasma levels of the platelet-derived neutrophil-activating chemokine C-X-C-motif ligand (CXCL) 4 (PF-4), the neutrophil attractant CXCL7 (NAP-2), and myeloperoxidase (MPO). The clinical-biological relevance of these variables was corroborated by specific associations with molecular-cellular, structural-radiological, hemodynamic, and clinical-functional parameters. Seventy consecutive patients fulfilling all predefined criteria entered analysis. Mean local CXCL4 (+ 39%: 571 vs 410 ng/ml, P = .0095) and CXCL7 (+ 9%: 693 vs 636 ng/ml, P = .013) concentrations were higher compared with self-controls. Local platelet counts were lower (- 10%: 347,582 vs 383,284/µl, P = .0052), whereas neutrophil counts were elevated (+ 10%: 6022 vs 5485/µl, P = 0.0027). Correlation analyses revealed associations between local platelet and neutrophil counts (r = 0.27, P = .034), and between CXCL7 and MPO (r = 0.24, P = .048). Local CXCL4 was associated with the angiographic degree of reperfusion following recanalization (r = - 0.2523, P = .0479). Functional outcome at discharge correlated with local MPO concentrations (r = 0.3832, P = .0014) and platelet counts (r = 0.288, P = .0181). This study provides human evidence of cerebral platelet activation and platelet-neutrophil interactions during AIS and points to the relevance of per-ischemic thrombo-inflammatory mechanisms to impaired reperfusion and worse functional outcome following recanalization.
Improved radiological examinations with newly developed 3D models may increase understanding of Meniere's disease (MD). The morphology and course of the vestibular aqueduct (VA) in the temporal bone might be related to the severity of MD. The presented study explored, if the VA of MD and non-MD patients can be grouped relative to its angle to the semicircular canals (SCC) and length using a 3D model. Scans of temporal bone specimens (TBS) were performed using micro-CT and micro flat panel volume computed tomography (mfpVCT). Furthermore, scans were carried out in patients and TBS by computed tomography (CT). The angle between the VA and the three SCC, as well as the length of the VA were measured. From these data, a 3D model was constructed to develop the vestibular aqueduct score (VAS). Using different imaging modalities it was demonstrated that angle measurements of the VA are reliable and can be effectively used for detailed diagnostic investigation. To test the clinical relevance, the VAS was applied on MD and on non-MD patients. Length and angle values from MD patients differed from non-MD patients. In MD patients, significantly higher numbers of VAs could be assigned to a distinct group of the VAS. In addition, it was tested, whether the outcome of a treatment option for MD can be correlated to the VAS.
Purpose
For further improvements in cochlear implantation, the measurement of the cochlear duct length (CDL) and the determination of the electrode contact position (ECP) are increasingly in the focus of clinical research. Usually, these items were investigated by multislice computed tomography (MSCT). The determination of ECP was only possible by research programs so far. Flat-panel volume computed tomography (fpVCT) and its secondary reconstructions (fpVCT\(_{SECO}\)) allow for high spatial resolution for the visualization of the temporal bone structures. Using a newly developed surgical planning software that enables the evaluation of CDL and the determination of postoperative ECP, this study aimed to investigate the combination of fpVCT and otological planning software to improve the implementation of an anatomically based cochlear implantation.
Methods
Cochlear measurements were performed utilizing surgical planning software in imaging data (MSCT, fpVCT and fpVCT\(_{SECO}\)) of patients with and without implanted electrodes.
Results
Measurement of the CDL by the use of an otological planning software was highly reliable using fpVCT\(_{SECO}\) with a lower variance between the respective measurements compared to MSCT. The determination of the inter-electrode-distance (IED) between the ECP was improved in fpVCT\(_{SECO}\) compared to MSCT.
Conclusion
The combination of fpVCT\(_{SECO}\) and otological planning software permits a simplified and more reliable analysis of the cochlea in the pre- and postoperative setting. The combination of both systems will enable further progress in the development of an anatomically based cochlear implantation.
Purpose
Patients suffering from aggressive systemic peripheral lymphoma with primary central nervous system involvement (PCL) are a rare and sparsely investigated population. Recommended treatment regimens include a combination of intrathecal and systemic chemotherapy as well as whole brain radiotherapy while offering relatively poor survival.
Methods
We conducted a single-center retrospective study that analyzed safety and outcome of 4 + 4 cycles Rituximab (R)-CHOP and R-high-dose Methotrexate (HD-MTX) for newly diagnosed, transplant-eligible patients ("Ping-Pong"), followed by Cytarabine (AraC)/Thiotepa (TT), BCNU/TT, and autologous hematologic stem cell transplantation (aHSCT). We retrospectively analyzed a set of 16 patients with high-intermediate or high-risk IPI status.
Results
Overall response rate to Ping-Pong was 100% measured by CT/MRI, including 93.75% complete remissions after BCNU/TT followed by PBSCT. One patient failed to qualify for high-dose chemotherapy due to progression when receiving Cytarabine/TT. All patients experienced grade III adverse events, 3 of them a grade IV adverse event. Estimated progression-free survival is 93.75% after a 4.8-year follow-up currently.
Conclusion
Our study suggests high effectivity of R-CHOP with mid-cycle MTX with aHSCT consolidation towards acceptable OS results in this challenging patient population.
Background
Anderson–Fabry disease (FD) is an X-linked lysosomal storage disorder with varying organ involvement and symptoms, depending on the underlying mutation in the alpha-galactosidase A gene (HGNC: GLA). With genetic testing becoming more readily available, it is crucial to precisely evaluate pathogenicity of each genetic variant, in order to determine whether there is or might be not a need for FD-specific therapy in affected patients and relatives at the time point of presentation or in the future.
Methods
This case series investigates the clinical impact of the specific GLA gene variant c.376A>G (p.Ser126Gly) in five (one heterozygous and one homozygous female, three males) individuals from different families, who visited our center between 2009 and 2021. Comprehensive neurological, nephrological and cardiac examinations were performed in all cases. One patient received a follow-up examination after 12 years.
Results
Index events leading to suspicion of FD were mainly unspecific neurological symptoms. However, FD-specific biomarkers, imaging examinations (i.e., brain MRI, heart MRI), and tissue-specific diagnostics, including kidney and skin biopsies, did not reveal evidence for FD-specific symptoms or organ involvement but showed normal results in all cases. This includes findings from 12-year follow-up in one patient with renal biopsy.
Conclusion
These findings suggest that p.Ser126Gly represents a benign GLA gene variant which per se does not cause FD. Precise clinical evaluation in individuals diagnosed with genetic variations of unknown significance should be performed to distinguish common symptoms broadly prevalent in the general population from those secondary to FD.
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition of up to 62%. However, primary and secondary resistance to PD-1/PD-L1 inhibition remains a so far unsolved clinical challenge since effective and safe treatment options for these patients are lacking.Fourteen patients with advanced (non-resectable stage III or stage IV, Union international contre le cancer 2017) Merkel cell carcinoma with primary resistance to the PD-L1 inhibitor avelumab receiving subsequent therapy (second or later line) with ipilimumab plus nivolumab (IPI/NIVO) were identified in the prospective multicenter skin cancer registry ADOREG. Five of these 14 patients were reported previously and were included in this analysis with additional follow-up. Overall response rate, progression-free survival (PFS), overall survival (OS) and adverse events were analyzed.All 14 patients received avelumab as first-line treatment. Thereof, 12 patients had shown primary resistance with progressive disease in the first tumor assessment, while two patients had initially experienced a short-lived stabilization (stable disease). Six patients had at least one systemic treatment in between avelumab and IPI/NIVO. In total, 7 patients responded to IPI/NIVO (overall response rate 50%), and response was ongoing in 4 responders at last follow-up. After a median follow-up of 18.85 months, median PFS was 5.07 months (95% CI 2.43—not available (NA)), and median OS was not reached. PFS rates at 12 months and 24 months were 42.9% and 26.8 %, respectively. The OS rate at 36 months was 64.3%. Only 3 (21%) patients did not receive all 4 cycles of IPI/NIVO due to immune-related adverse events.In this multicenter evaluation, we observed high response rates, a durable benefit and promising OS rates after treatment with later-line combined IPI/NIVO. In conclusion, our patient cohort supports our prior findings with an encouraging activity of second-line or later-line IPI/NIVO in patients with anti-PD-L1-refractory Merkel cell carcinoma.
Magnetic nanoparticles (MNPs) have been adapted for many applications, e.g., bioassays for the detection of biomarkers such as antibodies, by controlled engineering of specific surface properties. Specific measurement of such binding states is of high interest but currently limited to highly sensitive techniques such as ELISA or flow cytometry, which are relatively inflexible, difficult to handle, expensive and time-consuming. Here we report a method named COMPASS (Critical-Offset-Magnetic-Particle-SpectroScopy), which is based on a critical offset magnetic field, enabling sensitive detection to minimal changes in mobility of MNP ensembles, e.g., resulting from SARS-CoV-2 antibodies binding to the S antigen on the surface of functionalized MNPs. With a sensitivity of 0.33 fmole/50 µl (≙7 pM) for SARS-CoV-2-S1 antibodies, measured with a low-cost portable COMPASS device, the proposed technique is competitive with respect to sensitivity while providing flexibility, robustness, and a measurement time of seconds per sample. In addition, initial results with blood serum demonstrate high specificity.